<div id="readability-page-1">04:17 PM EST, 12/18/2025 (MT Newswires) -- Tilray Brands ( TLRY ) unit Tilray Medical said Thursday it plans to advance its US medical cannabis operations after federal cannabis rescheduling and related regulatory updates.The company said that, in conjunction with the regulatory changes, it will form Tilray Medical USA.&#34;We support President Trump's decision to reschedule cannabis as a constructive and necessary evolution of US federal policy,&#34; said Tilray Brands ( TLRY ) Chief Executive Irwin Simon.President Donald Trump on Thursday signed an executive order to ease restrictions on marijuana in a move that the White House said would pave the way for conducting medical research on the drug.Trump's order directs Attorney General Pamela Bondi to reclassify marijuana as a Schedule III drug under the Controlled Substance Act, according to a White House fact sheet. Marijuana is currently controlled as a Schedule I substance, which includes drugs with no accepted medical use and a high potential for abuse. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

TLRY

Tilray Brands 的子公司 Tilray Medical 計劃在聯邦大麻重新分類和監管更新後擴展其在美國的醫療大麻業務。這一舉措與特朗普總統的行政命令一致，旨在將大麻重新分類為第三類藥物，從而促進醫學研究。Tilray 支持這一政策變化，認為這是美國聯邦政策演變的積極一步

在監管進展之後，Tilray Brands 的一個部門將加速其在美國的醫用大麻業務